Ginkgo Bioworks Launches Automated ADME Profiling Service to Accelerate Small Molecule Drug Discovery
核心洞察
Ginkgo Bioworks has launched a high-throughput ADME (搜索) profiling service using proprietary RAC automation (搜索) technology to accelerate small molecule (搜索) drug development.
The service offers competitive pricing with a guarantee to match or beat quotes from Chinese and international vendors while maintaining US-based operations.
The platform generates model-ready datasets optimized for machine learning applications, enabling researchers to prioritize drug candidates and train predictive models more efficiently.
Ginkgo Bioworks (NYSE: DNA) has announced the launch of a new high-throughput ADME (搜索) (Absorption, Distribution, Metabolism, and Excretion) profiling service through its Ginkgo Datapoints (搜索) platform, leveraging proprietary RAC automation (搜索) technology to deliver cost-effective drug discovery solutions. The service aims to dramatically accelerate and de-risk the small molecule (搜索) drug development pipeline while offering competitive pricing against international vendors.
Competitive Pricing Strategy
The company has positioned its ADME (搜索) service with an aggressive pricing strategy, promising to match or beat quotes from Chinese and other international vendors while maintaining all operations within the United States. "We will price match any ADME service quote you get (including from Chinese or other international vendors), though we hope to beat them on per-compound pricing out of the gate anyway," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks.
Kelly emphasized that the company's automation capabilities and operational scale enable them to offer "best-in-class pricing and quality" in the ADME (搜索) profiling market.
Technology and Service Features
The new ADME (搜索) profiling service incorporates several key technological advantages designed for modern drug discovery workflows:
The platform utilizes scalable, automated workflows that represent Ginkgo's standard approach to laboratory operations. The service is specifically optimized for machine learning applications, providing early access to rich ADME (搜索) data that enables researchers to prioritize drug candidates and train predictive models with enhanced speed and efficiency.
A critical feature of the service is its generation of model-ready datasets enriched with structured metadata specifically designed for AI-powered insights. This approach addresses common challenges in drug discovery data management by eliminating fragmented data and reducing delays in the research process.
Market Positioning and Impact
The ADME (搜索) service launch represents Ginkgo's strategic expansion into providing specialized services for the biopharmaceutical industry. The company describes the offering as "biology built for algorithms," emphasizing the integration of biological research with computational approaches that are increasingly central to modern drug discovery.
The service is designed to keep pace with modern discovery cycles through rapid turnaround times, addressing the industry's need for faster decision-making in early-stage drug development. By providing cost-effective pricing built for high-throughput applications, the platform aims to make comprehensive ADME (搜索) profiling more accessible to researchers across different scales of operation.
Company Background
Ginkgo Bioworks positions itself as a leading platform for cell programming and biosecurity, building tools designed to make biology easier to engineer. Beyond the new ADME (搜索) service, the company operates Ginkgo Automation, which sells modular, integrated laboratory automation systems, and Ginkgo Biosecurity, which develops infrastructure and technologies for biological threat detection and response.
The launch of the ADME (搜索) profiling service reinforces Ginkgo's commitment to providing comprehensive, cost-effective services to the biopharmaceutical industry while maintaining competitive advantages through automation and scale.